Subscription Pricing Could Expand Access to HIV Prevention Breakthrough

Figure 2 from the PURPOSE-1 trial changed the world. Between gray and red bars representing the study’s background HIV incidence and the arms randomized to receive oral pre-exposure prophylaxis (PrEP) was white space filled only by a previously unimaginable number: zero.

Zero infections over one year among the 2,134 cisgender adolescent girls and young women who received the novel long-acting injectable antiretroviral lenacapavir. Read the rest...